DCE-MRI as Pazopanib Biomarker in Metastatic Renal Cancer

Trial Profile

DCE-MRI as Pazopanib Biomarker in Metastatic Renal Cancer

Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Renal cell carcinoma
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 12 Jun 2017 Status changed from completed to discontinued.
    • 10 Jun 2017 Biomarkers information updated
    • 29 Jun 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top